130 related articles for article (PubMed ID: 22960860)
21. PDE4 and PDE5 regulate cyclic nucleotides relaxing effects in human umbilical arteries.
Santos-Silva AJ; Cairrão E; Morgado M; Alvarez E; Verde I
Eur J Pharmacol; 2008 Mar; 582(1-3):102-9. PubMed ID: 18234184
[TBL] [Abstract][Full Text] [Related]
22. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3.
Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW
Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473
[TBL] [Abstract][Full Text] [Related]
23. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents.
Hutson PH; Finger EN; Magliaro BC; Smith SM; Converso A; Sanderson PE; Mullins D; Hyde LA; Eschle BK; Turnbull Z; Sloan H; Guzzi M; Zhang X; Wang A; Rindgen D; Mazzola R; Vivian JA; Eddins D; Uslaner JM; Bednar R; Gambone C; Le-Mair W; Marino MJ; Sachs N; Xu G; Parmentier-Batteur S
Neuropharmacology; 2011 Sep; 61(4):665-76. PubMed ID: 21619887
[TBL] [Abstract][Full Text] [Related]
24. Phosphodiesterase 5 (PDE5) inhibition, ANP and NO rapidly reduce epididymal duct contractions, but long-term PDE5 inhibition in vivo does not.
Mietens A; Tasch S; Feuerstacke C; Eichner G; Volkmann J; Schermuly RT; Grimminger F; Müller D; Middendorff R
Mol Cell Endocrinol; 2012 Feb; 349(2):145-53. PubMed ID: 21996373
[TBL] [Abstract][Full Text] [Related]
25. Expression and distribution of key enzymes of the cyclic GMP signaling in the human clitoris: relation to phosphodiesterase type 5 (PDE5).
Ückert S; Oelke M; Albrecht K; Breitmeier D; Kuczyk MA; Hedlund P
Int J Impot Res; 2011; 23(5):206-12. PubMed ID: 21697861
[TBL] [Abstract][Full Text] [Related]
26. Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line.
Wunder F; Tersteegen A; Rebmann A; Erb C; Fahrig T; Hendrix M
Mol Pharmacol; 2005 Dec; 68(6):1775-81. PubMed ID: 16150925
[TBL] [Abstract][Full Text] [Related]
27. Diagnostic value of adenosine deaminase activity in benign and malignant breast tumors.
Aghaei M; Karami-Tehrani F; Salami S; Atri M
Arch Med Res; 2010 Jan; 41(1):14-8. PubMed ID: 20430249
[TBL] [Abstract][Full Text] [Related]
28. Localization of cyclic guanosine 3',5'-monophosphate-hydrolyzing phosphodiesterase type 9 in rat brain by nonradioactive in situ hydridization.
van Staveren WC; Markerink-van Ittersum M
Methods Mol Biol; 2005; 307():75-84. PubMed ID: 15988056
[TBL] [Abstract][Full Text] [Related]
29. Characterization of renal ecto-phosphodiesterase.
Jackson EK; Ren J; Zacharia LC; Mi Z
J Pharmacol Exp Ther; 2007 May; 321(2):810-5. PubMed ID: 17308037
[TBL] [Abstract][Full Text] [Related]
30. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate.
Uckert S; Oelke M; Stief CG; Andersson KE; Jonas U; Hedlund P
Eur Urol; 2006 Apr; 49(4):740-5. PubMed ID: 16460876
[TBL] [Abstract][Full Text] [Related]
32. The role of STS and OATP-B mRNA expression in predicting the clinical outcome in human breast cancer.
Al Sarakbi W; Mokbel R; Salhab M; Jiang WG; Reed MJ; Mokbel K
Anticancer Res; 2006; 26(6C):4985-90. PubMed ID: 17214375
[TBL] [Abstract][Full Text] [Related]
33. Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in breast carcinoma by real-time polymerase chain reaction.
Iwao K; Miyoshi Y; Egawa C; Ikeda N; Tsukamoto F; Noguchi S
Cancer; 2000 Oct; 89(8):1732-8. PubMed ID: 11042568
[TBL] [Abstract][Full Text] [Related]
34. Implications of PDE4 structure on inhibitor selectivity across PDE families.
Ke H
Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
[TBL] [Abstract][Full Text] [Related]
35. Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue.
Uckert S; Sormes M; Kedia G; Scheller F; Knapp WH; Jonas U; Stief CG
Urology; 2008 Mar; 71(3):526-30. PubMed ID: 18342202
[TBL] [Abstract][Full Text] [Related]
36. [Relationship between cyclic nucleotide phosphodiesterases (cPDE) and some patho-biologic behaviors of stomach cancer--I. Histochemical studies of CPDE in stomach cancer tissues].
Xin Y
Zhonghua Zhong Liu Za Zhi; 1989 Mar; 11(2):117-20. PubMed ID: 2553363
[TBL] [Abstract][Full Text] [Related]
37. cAMP phosphodiesterase activity evaluation in human carcinoma of salivary glands.
Spoto G; della Malva M; Rubini C; Fioroni M; Piattelli A; Serra E; Di Nicola M; Santoleri F
Nucleosides Nucleotides Nucleic Acids; 2006; 25(9-11):1113-7. PubMed ID: 17065074
[TBL] [Abstract][Full Text] [Related]
38. Phosphodiesterase inhibitors in airways disease.
Fan Chung K
Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
[TBL] [Abstract][Full Text] [Related]
39. Multiple cyclic nucleotide phosphodiesterases in human trabecular meshwork cells.
Zhou L; Thompson WJ; Potter DE
Invest Ophthalmol Vis Sci; 1999 Jul; 40(8):1745-52. PubMed ID: 10393044
[TBL] [Abstract][Full Text] [Related]
40. Characterization of 3',5' cyclic nucleotide phosphodiesterase activity in Y79 retinoblastoma cells: absence of functional PDE6.
White JB; Thompson WJ; Pittler SJ
Mol Vis; 2004 Oct; 10():738-49. PubMed ID: 15480303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
